{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:41:50Z","timestamp":1789180910617,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.rceng.2024.01.006","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T20:32:17Z","timestamp":1706819537000},"page":"167-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Systematic review of clinical trials on antithrombotic therapy with factor XI inhibitors"],"prefix":"10.1016","volume":"224","author":[{"given":"A.","family":"Franco-Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mu\u00f1oz-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Torres-Macho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bustamante-Fermosel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Ancos-Aracil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Madro\u00f1al-Cerezo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rceng.2024.01.006_bib0005","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.rceng.2024.01.006_bib0010","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1161\/STROKEAHA.117.017549","article-title":"Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis","volume":"48","author":"Ntaios","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.rceng.2024.01.006_bib0015","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: Evidence from phase 3 trials","volume":"124","author":"Van Es","year":"2014","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.rceng.2024.01.006_bib0020","doi-asserted-by":"crossref","first-page":"e1143","DOI":"10.1212\/WNL.0000000000005207","article-title":"Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin","volume":"90","author":"Kurogi","year":"2018","journal-title":"Neurology"},{"issue":"9921","key":"10.1016\/j.rceng.2024.01.006_bib0025","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.rceng.2024.01.006_bib0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.28033","article-title":"Clinical outcomes of direct oral anticoagulants vs warfarin for extended treatment of venous thromboembolism","volume":"6","author":"Fang","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rceng.2024.01.006_bib0035","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MBC.0000000000001153","article-title":"Comparing the efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis","volume":"33","author":"Wu","year":"2022","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rceng.2024.01.006_bib0040","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ahj.2012.03.011","article-title":"A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (REALIGN)","volume":"163","author":"Van de Werf","year":"2012","journal-title":"Am Heart J."},{"key":"10.1016\/j.rceng.2024.01.006_bib0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ahj.2020.06.014","article-title":"Rationale and design of PROACT Xa: a randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve","volume":"227","author":"Jawitz","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.rceng.2024.01.006_bib0050","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.rceng.2024.01.006_bib0055","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/ATVBAHA.118.312130","article-title":"Intrinsic pathway of coagulation and thrombosis","volume":"39","author":"Grover","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl 2","key":"10.1016\/j.rceng.2024.01.006_bib0060","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0049-3848(16)30354-1","article-title":"The hemostatic role of factor XI","volume":"141 Suppl 2","author":"Puy","year":"2016","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.rceng.2024.01.006_bib0065","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.rceng.2024.01.006_bib0070","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1046\/j.1538-7836.2003.00431.x","article-title":"The function of factor XI in tissue factor-initiated thrombin generation","volume":"1","author":"Butenas","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.rceng.2024.01.006_bib0075","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1055\/s-0033-1353420","article-title":"Congenital factor XI deficiency: an update","volume":"39","author":"Duga","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"9","key":"10.1016\/j.rceng.2024.01.006_bib0080","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.rceng.2024.01.006_bib0085","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of Factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2024.01.006_bib0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.rceng.2024.01.006_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"3","key":"10.1016\/j.rceng.2024.01.006_bib0100","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"FXI-ASO TKA Investigators. Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.rceng.2024.01.006_bib0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.rceng.2024.01.006_bib0110","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.rceng.2024.01.006_bib0115","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.rceng.2024.01.006_bib0120","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/a-2043-0346","article-title":"Factor XI inhibitors in early clinical trials: a meta-analysis","volume":"123","author":"Galli","year":"2023","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rceng.2024.01.006_bib0125","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.rceng.2024.01.006_bib0130","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.rceng.2024.01.006_bib0135","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.rceng.2024.01.006_bib0140","unstructured":"Sharma M., Molina Carlos A., Hankey Graeme J; for the AXIOMATIC-SSP Steering Committee and Investigators. Efficacy and Safety of the FXIa Inhibitor Milvexian for Secondary Stroke Prevention: Final Results of the AXIOMATIC-SSP Dose-finding Randomized Trial. https:\/\/www.phri.ca\/wp-content\/uploads\/2022\/09\/AXIOMATIC-SSP_ESC22.pdf (\u00faltimo acceso 3 de septiembre de 2023)."},{"issue":"4","key":"10.1016\/j.rceng.2024.01.006_bib0145","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.rceng.2024.01.006_bib0150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","article-title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Frere","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.rceng.2024.01.006_bib0155","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.rceng.2024.01.006_bib0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/STROKEAHA.117.018395","article-title":"Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis","volume":"49","author":"Proietti","year":"2018","journal-title":"Stroke"},{"key":"10.1016\/j.rceng.2024.01.006_bib0165","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijcard.2017.11.087","article-title":"Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in\u2019 real-world\u2019 atrial fibrillation patients: a comparison with optimally acenocoumarol anticoagulated patients","volume":"254","author":"Esteve-Pastor","year":"2018","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.rceng.2024.01.006_bib0170","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.amjmed.2016.09.012","article-title":"Registries in atrial fibrillation: from trials to real-life clinical practice","volume":"130","author":"Mazurek","year":"2017","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.rceng.2024.01.006_bib0175","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.medcli.2023.03.011","article-title":"Direct-acting oral anticoagulants in antiphospholipid syndrome: a systematic review","volume":"161","author":"Gir\u00f3n-Ortega","year":"2023","journal-title":"Med Clin (Barc)"},{"issue":"2","key":"10.1016\/j.rceng.2024.01.006_bib0180","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1160\/TH13-02-0150","article-title":"Gastrointestinal bleeding with the new oral anticoagulants\u2014defining the issues and the management strategies","volume":"110","author":"Desai","year":"2013","journal-title":"Thromb Haemost"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887424000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887424000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:50:46Z","timestamp":1762419046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2254887424000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2254887424000171"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2024.01.006","relation":{},"ISSN":["2254-8874"],"issn-type":[{"value":"2254-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review of clinical trials on antithrombotic therapy with factor XI inhibitors","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2024.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2024.01.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights reserved.","name":"copyright","label":"Copyright"}]}}